TG TherapeuticsTGTX
About: TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Employees: 352
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
121% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 38
40% more funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 7 (+2) [Q1 2025]
33% more capital invested
Capital invested by funds: $2.92B [Q4 2024] → $3.87B (+$958M) [Q1 2025]
23% more call options, than puts
Call options by funds: $118M | Put options by funds: $96.4M
13% more funds holding
Funds holding: 326 [Q4 2024] → 368 (+42) [Q1 2025]
4% more repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 114
0.33% more ownership
Funds ownership: 62.23% [Q4 2024] → 62.55% (+0.33%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for TGTX.
Financial journalist opinion
Based on 5 articles about TGTX published over the past 30 days
